skip to Main Content

Novel Metabolic Therapy Demonstrates Activity in Metastatic Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
SM-88, a novel compound that attacks oncogenic metabolic pathways, is under development for patients with metastatic pancreatic cancer and other solid tumors, raising the potential for a tumor-agnostic therapy.

The agent is being explored in the phase II Tyme-88-Panc trial in patients with metastatic pancreatic adenocarcinoma that shows radiographic disease progression on or after at least 1 line of any chemotherapy. Read more . . . 


Back To Top